UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 610, 2016

EPIRUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-51171		04-3514457
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

699 Boylston Street

Eighth Floor

Boston, MA 02116

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (617) 600-3497

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

OnItem ~~May 9, 2016, EPIRUS Biopharmaceuticals, Inc~~1.01 ~~(“EPIRUS”~~Entry orinto ~~the~~a ~~“Company”)~~Material ~~announced~~Definitive ~~the reprioritization of the Company’s pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases~~Agreement. This will involve, among other things, reallocating the Company’s resources to focus on the development of BOW080 (eculizumab; reference biologic Soliris®) for the potential treatment of ultra-rare blood disorders and BOW070 (tocilizumab; reference biologic Actemra®) for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman’s disease.

~~Item~~On 2June 13, 2016, EPIRUS Biopharmaceuticals, Inc.05 ~~Costs~~(“EPIRUS” ~~Associated~~or the “Company”) entered into a binding term sheet (the “Binding Term Sheet”) with ~~Exit~~Zakłady Farmaceutyczne “Polpharma” S.A. (“Polpharma”), pursuant to which the Company will sell to Polpharma all of the outstanding shares of EPIRUS Biopharmaceuticals (Netherlands) B.V. (“EPIRUS Netherlands”, formerly known as Bioceros Holdings, N.V. (“Bioceros”)), in exchange for a payment of $3.5 million in cash, subject to adjustment for any remaining outstanding cash or ~~Disposal~~net ~~Activities~~debt held by EPIRUS Netherlands. EPIRUS Netherlands has been the Company’s technical cell-line generation and process development site since its acquisition by the Company in September 2015.

OnIn ~~May 9, 2016, in~~ connection with the ~~matters~~transactions ~~described~~contemplated ~~above,~~by the ~~Company~~Binding ~~announced~~Term ~~staff~~Sheet, ~~reductions~~Polpharma ofwill upacquire toownership ~~approximately 40%~~ of ~~the~~EPIRUS ~~Company~~Netherlands’s ~~workforce,~~proprietary asCHOBC cell aline ~~result~~platform, ofall ~~the~~related ~~suspension~~intellectual ofproperty ~~work on its lead program~~rights, ~~BOW015 (infliximab, reference biologic Remicade®). The Company is engaged in~~ a ~~strategic~~fully ~~review~~equipped oflaboratory ~~its~~and ~~options,~~bioreactor ~~including~~capabilities ~~with~~designed ~~respect~~for to the ~~BOW015~~development ~~program,~~of ~~which~~monoclonal ~~may~~antibodies ~~include partnerships, divestitures~~ and~~/or~~ ~~other~~protein ~~value-generating alternatives~~therapeutics. ~~The~~EPIRUS ~~Company’s~~will ~~new~~retain ~~focus~~exclusive onrights ~~biosimilars~~to ~~that~~develop ~~treat~~BOW080 ~~rare~~(eculizumab; ~~diseases~~reference ~~necessitates~~biologic aSoliris®) ~~restructuring~~for of the ~~Company’s~~potential ~~operations~~treatment ~~and~~of aultra-rare ~~corresponding~~blood ~~reduction~~disorders inand ~~workforce,~~BOW070 to(tocilizumab; ~~align~~reference ~~its~~biologic ~~resources~~Actemra®) ~~more~~for ~~closely~~the ~~with~~potential ~~its~~treatment ~~corporate objectives. The Company notified approximately 20%~~ of ~~its~~an ~~employees~~uncommon ~~that~~lymphoproliferative ~~they~~disorder ~~are~~known ~~affected~~as byCastleman’s ~~the~~disease. With ~~initial~~this ~~stage~~sale of ~~this~~EPIRUS ~~reduction in force on May 9~~Netherlands, ~~2016, and intends to complete~~ the ~~workforce reduction by the end of the second quarter of 2016. The~~ Company’s ~~decision~~will continue to ~~suspend~~pursue its ~~BOW015~~restructuring ~~program is based on cost-savings~~efforts, ~~not~~including ~~technical reasons, and~~ the ~~program~~possible ~~remains~~creation ~~ready~~of toa ~~commence~~separate ~~its~~company ~~planned~~focused ~~global~~on ~~Phase~~rare 3disease ~~clinical~~biological ~~study~~product opportunities.

~~The~~Pursuant ~~Company~~to ~~intends~~the toBinding ~~provide~~Term ~~contingent~~Sheet, ~~and~~the ~~deferred~~parties ~~severance~~have ~~payments~~agreed to ~~all~~close ~~employees whose employment is being terminated as part of~~ the ~~workforce~~sale ~~reduction.~~transaction Inby ~~the~~no ~~case~~later ofthan ~~affected~~June 24, ~~members~~2016 of (the ~~Company’s~~“Closing ~~management team~~Date”), with the ~~amount~~parties ofagreeing ~~such~~to ~~severance~~negotiate ~~payments~~and ~~would~~execute bea ~~made~~definitive ~~pursuant~~agreement toreflecting the ~~terms~~provisions of the ~~Company’s~~Binding ~~Severance~~Term ~~Plan,~~Sheet ~~and~~by ~~for~~such ~~all~~date. The ~~other~~Binding ~~affected~~Term ~~employees,~~Sheet ~~such~~further ~~payments~~provides ~~would~~that beif ~~equal~~the toparties ~~three~~fail ~~(3) months’~~to ~~salary~~execute ~~and~~a ~~COBRA~~definitive ~~benefits.~~agreement ~~All~~by of the ~~foregoing~~Closing ~~severance payments will~~Date, ~~however,~~the besale ~~deferred~~of ~~pending~~EPIRUS ~~the~~Netherlands ~~Company’s~~will ~~ability~~nonetheless tobe ~~complete~~consummated ~~its~~on ~~next~~June 24, ~~material~~2016 ~~equity~~in ~~capital~~accordance ~~financing~~with in the ~~near~~terms ~~term,~~set asforth toin ~~which~~ the ~~Company~~Binding ~~can~~Term ~~make no assurance~~Sheet.

~~EPIRUS~~At ~~estimates~~ the ~~staff~~closing ~~reductions~~of ~~and~~the ~~related~~EPIRUS ~~operational~~Netherlands ~~changes~~sale, EPIRUS will ~~result~~be inobligated ~~savings~~to ofaccelerate ~~approximately~~the final payment of $721.7 million in ~~operating expenses, with estimated one-time severance and other~~ cash ~~charges related~~ to the ~~workforce~~former ~~reduction~~shareholders ~~and~~of ~~the~~Bioceros ~~suspension~~pursuant ofto ~~work~~that oncertain ~~the~~Stock ~~BOW015~~Purchase ~~program~~Agreement ofdated ~~approximately~~as $3of ~~million~~September 9, ~~expected~~2015, toamong beEPIRUS, ~~recorded~~Bioceros, in the ~~second~~sellers ~~quarter~~identified oftherein, ~~2016.~~and ~~Following~~Oscar ~~the~~Schoots ~~staff reductions~~ and ~~related~~Carine ~~operational~~van ~~changes~~den ~~described~~Brink inas ~~this Form 8-K,~~ the ~~Company~~representatives ~~expects~~of tothe ~~have~~sellers, ~~sufficient~~which ~~cash~~final ~~resources~~payment was to ~~continue~~have ~~its~~been ~~operations~~made ~~through~~on ~~the~~September 9, ~~second quarter of~~ 2016.

EPIRUS does not anticipate that there will be any further material future cash expenditures associated with the workforce reduction. The estimated savings and costs noted above are subject to a number of assumptions. Actual results and experience may differ materially as a result of various important factors, including the risks and uncertainties described under the heading “Forward-Looking Statements” in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated by reference herein. EPIRUS may incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction and changes to operations.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

(b) Effective as of May 6, 2016, Mr. Amit Munshi, the Company’s President and Chief Executive Officer and a member of its Board of Directors (the “Board”) has resigned from each of those positions.

(c) On May 6, 2016, the Board appointed Scott Rocklage, Ph.D., a current member of the Board, as the Company’s acting Chief Executive Officer. Dr. Rocklage will not be separately compensated for serving in this capacity. Biographical information about Dr. Rocklage can be found in the Company’s Annual Report on Form 10-K, as amended, filed on April 29, 2016 (the “Annual Report”) under the section entitled “Directors — Director Biographies,” which biographical information is incorporated by reference into this Item 5.02. Information about his compensation as a non-employee director can be found in the Annual Report under the section entitled “Directors — Director Compensation,” which information is incorporated by reference into this Item 5.02.

On May 6, 2016, the Board appointed Michael Wyand, DVM, Ph.D., as the Company’s President and Chief Operating Officer. Dr. Wyand’s compensation shall remain as previously disclosed in the Annual Report under the section entitled “Executive Compensation,” which information is incorporated by reference into this Item 5.02. Biographical information about Dr. Wyand can be found in the Annual Report under the section entitled “Executive Officers,” which biographical information is incorporated by reference into this Item 5.02.

For information about certain relationships we have with Drs. Rocklage and Wyand, see the section entitled “Certain Relationships and Related Party Transactions —Transactions with our Directors, Executive Officers, Key Employees and Significant Stockholders” of the Annual Report, which disclosure is incorporated by reference into this Item 5.02.

Item 8.01 Other Events.

On ~~May~~June 910, 2016, ~~EPIRUS~~following ~~issued~~consensual adiscussions ~~press~~with ~~release~~Hercules ~~announcing~~Technology ~~certain~~Growth ofCapital, Inc. (“Hercules”) relating to amounts owed under the ~~matters~~Loan ~~described~~and inSecurity ~~this~~Agreement ~~Current~~dated ~~Report~~as onof ~~Form~~September ~~8-K~~30, ~~which~~2014 is(the ~~filed~~“Loan asAgreement”) ~~Exhibit 99~~between the Company and Hercules, the Company repaid $8.0 million of the outstanding $14.1 tomillion ~~this~~in ~~Current~~principal ~~Report~~amount onowed ~~Form 8-K~~pursuant to the Loan Agreement.

~~Item 9.01 Financial Statements and Exhibits.~~2

~~(d) Exhibits~~ SIGNATURES

Exhibit Number		Description
99.1		Press release of EPIRUS Biopharmaceuticals, Inc. dated May 9, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 14, 2016	EPIRUS BIOPHARMACEUTICALS, INC.

	By:	/s/ Scott Rocklage
	Name:	Scott Rocklage
	Title:	Chief Executive Officer

~~SIGNATURES~~3

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 9, 2016	EPIRUS BIOPHARMACEUTICALS, INC.
	By:	/s/ Scott Rocklage
	Name:	Scott Rocklage
	Title:	Acting Chief Executive Officer

Exhibit Number		Description
99.1		Press release of EPIRUS Biopharmaceuticals, Inc. dated May 9, 2016

Filing Compare · EPIRUS Biopharmaceuticals, Inc.